What do the halo sign and reverse halo (atoll) sign on chest CT indicate, and how should they be managed in immunocompromised versus non‑immunocompromised patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Halo and Reverse Halo Sign: Diagnostic Significance and Management

Direct Answer

In immunocompromised patients, the halo sign strongly suggests early invasive fungal infection (particularly aspergillosis) and warrants immediate empiric antifungal therapy with voriconazole, while the reverse halo sign indicates either fungal infection (aspergillosis or mucormycosis) or organizing pneumonia depending on specific imaging features and neutrophil status 1, 2.

Halo Sign

What It Indicates

The halo sign is ground-glass opacity surrounding a pulmonary nodule or mass. In severely immunocompromised patients, this sign is highly suggestive of early angioinvasive fungal infection 1.

Key diagnostic considerations by immune status:

  • Immunocompromised patients: Invasive pulmonary aspergillosis is the primary concern (78% of cases in one series) 3
  • Immunocompetent patients: Primary neoplasm is most common (64% of cases) 3

Distinguishing Features

Imaging characteristics that favor infection in immunocompromised hosts 3:

  • Multiple lesions with random distribution (highly specific for infection)
  • Thicker halos (statistically significant for infectious etiology)
  • Bilateral involvement

Management Approach

For immunocompromised patients with halo sign:

  1. Initiate empiric antifungal therapy immediately - do not wait for microbiological confirmation 4, 1

    • Primary agent: Voriconazole (strong recommendation for invasive aspergillosis) 4
    • Alternative: Lipid formulation amphotericin B if voriconazole contraindicated 4
  2. Obtain diagnostic specimens concurrently:

    • Serum galactomannan (GM) testing 4
    • Respiratory samples for culture and molecular testing
    • Consider bronchoscopy with bronchoalveolar lavage
  3. Serial GM monitoring to assess therapeutic response in hematologic malignancy/HSCT patients 4

For immunocompetent patients:

  • Pursue tissue diagnosis to exclude malignancy
  • Consider infectious workup if clinical context suggests infection

Reverse Halo Sign (Atoll Sign)

What It Indicates

The reverse halo sign is focal ground-glass opacity surrounded by a ring or crescent of consolidation. The differential diagnosis differs substantially based on immune status 2, 5.

Diagnostic Algorithm by Immune Status

In immunocompromised patients (hematologic malignancy, neutropenia, transplant):

Infection is most common (66% of cases) 2:

  • Aspergillosis (20%) - as common as mucormycosis overall due to higher frequency 2
  • Mucormycosis (19%) - classically associated but not more common than aspergillosis 2
  • Bacterial pneumonia

Features favoring infectious cause 2:

  • Neutropenia present
  • Thick rim (>3mm consolidation)
  • Dense central ground-glass attenuation
  • Larger lesion diameter
  • Pleural effusion

Organizing pneumonia (26%) - more common in solid organ transplant recipients 2

Specific Imaging Features for Differential

Nodular walls or nodules inside the halo: Highly suggestive of granulomatous diseases (tuberculosis, paracoccidioidomycosis, sarcoidosis) 6

Smooth walls, solitary, peripheral distribution: Suggests pulmonary infarction (most common cause overall at 42% in general population) 7

Management Approach

For immunocompromised patients with reverse halo sign:

  1. Assess neutrophil status immediately:

    • If neutropenic: Presume fungal infection → initiate broad-spectrum antifungal coverage
      • Voriconazole for aspergillosis coverage 4
      • Consider adding amphotericin B if mucormycosis suspected (thick rim, rapid progression) 4
  2. Evaluate imaging characteristics:

    • Thick rim (>3mm) + neutropenia + dense central opacity = treat as invasive fungal infection 2
    • Thin rim + non-neutropenic + solid organ transplant = consider organizing pneumonia → may require corticosteroids 2
  3. Obtain microbiological confirmation:

    • Serum galactomannan and (1→3)-β-D-glucan 4
    • Respiratory cultures including fungal
    • Bronchoscopy with biopsy if diagnosis uncertain and patient stable enough
  4. For organizing pneumonia diagnosis (after excluding infection):

    • High-dose corticosteroids
    • Monitor for radiological improvement

For immunocompetent patients:

  • Pulmonary embolism workup if smooth-walled, solitary, peripheral 7
  • Consider tuberculosis if nodular pattern 6, 8
  • Tissue diagnosis if features atypical

Critical Pitfalls to Avoid

  1. Do not delay antifungal therapy in immunocompromised patients waiting for microbiological confirmation - the halo and reverse halo signs justify preemptive treatment 1

  2. Do not assume reverse halo sign = mucormycosis exclusively - aspergillosis is equally common in immunocompromised populations 2

  3. Do not overlook organizing pneumonia in solid organ transplant recipients with reverse halo sign, especially if non-neutropenic 2

  4. Do not miss pulmonary embolism as the most common cause of reverse halo sign in general populations 7

  5. Nodular reverse halo sign patterns require tuberculosis exclusion, particularly in high-risk populations including hemodialysis patients 6, 8

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.